Last reviewed · How we verify
NCT02556437
Randomized, Single-blind, Cross-over Study Investigating the Non-inferiority of Efficacy and Safety of HyQvia in Comparison With Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy
Phase 2 trial testing HyQvia in Multifocal Motor Neuropathy in 18 participants. Completed in 1 May 2018.
1 May 2018
Quick facts
| Lead sponsor | Johannes Jakobsen |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 1 June 2016 |
| Primary completion | 1 May 2018 |
| Estimated completion | 1 May 2018 |
| Sites | 2 locations across Denmark |
Drugs / interventions tested
Conditions studied
- Multifocal Motor Neuropathy — all drugs for Multifocal Motor Neuropathy →
Sponsor
Johannes Jakobsen — full company profile →
Who can join
Adults 18 to 90, any sex, with Multifocal Motor Neuropathy. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Changes in isometric muscle strength
Time frame: Evaluation at week 0, 12, 24, 36, 48
Measurement of isometric muscle strength of four involved muscle groups
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of HyQvia (Immunoglobulin 10% with recombinant hyaluronidase) with conventional subcutaneous immunoglobulin treatment in patients with Multifocal Motor Neuropathy (MMN).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
Briani C, Visentin A. · · 2022 · cited 39× · PMID 35349079 · DOI 10.1007/s13311-022-01222-x
Verify or expand the search:
- PubMed search for NCT02556437
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HyQvia
Trials testing the same drug.
- NCT06895967 — A Study of TAK-881 and HyQvia in Healthy Adults · Phase 1 · completed
- NCT03054181 — Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) · completed
Other recruiting trials for Multifocal Motor Neuropathy
Currently open trials in the same condition.
- NCT06537999 — A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy · Phase 2 · recruiting
- NCT05988073 — A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy · active not recruiting
- NCT06040567 — Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02556437 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johannes Jakobsen
- Last refreshed: 14 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02556437.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing